ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Sjögren’s syndrome"

  • Abstract Number: 2180 • ACR Convergence 2023

    Salivary and Plasma Mitochondrial Double-strand RNAs as a Diagnostic Biomarker for Sjӧgren Syndrome

    SE RIM CHOI1, Jee-in Lee2, Yong Seok Choi3, You-Jung Ha3, Eun Ha Kang3 and Yun Jong Lee4, 1Seoul National University Bundang Hospital, Seoul, South Korea, 2Seoul National University of Bundang Hospital, Seongnam, South Korea, 3Seoul National University Bundang Hospital, Seongnam, South Korea, 4Division of Rheumatology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam-si, South Korea

    Background/Purpose: Since mitochondrial double-stranded RNAs (mt-dsRNAs), an endogenous activator of interferon signaling, are elevated in primary Sjӧgren's syndrome (pSS), we evaluated their association with the…
  • Abstract Number: 2335 • ACR Convergence 2023

    Defining a Basket Population for ANA+ Arthritis Trials

    Jack Arnold1, Md Yuzaiful Md Yusof1, Lucy Carter2, Zoe Wigston1 and Ed Vital1, 1University of Leeds, Leeds, United Kingdom, 2University of Leeds, Hartlepool, United Kingdom

    Background/Purpose: Musculoskeletal (MSK) manifestations are common in systemic lupus erythematosus (SLE) and other ANA-associated rheumatic musculoskeletal diseases (ANA-RMDs). Presently clinical trials recruit patients from individual…
  • Abstract Number: 0037 • ACR Convergence 2023

    New Histological Approach in Spatial Transcriptomics Implicates Glandular Cell Involvement in Pathophysiology of Sjögren’s Disease

    Paulina Czarnota1, Rick Wilbrink2, Bhuwan Khatri1, Anna Stolarczyk1, Cherilyn Pritchett Frazee1, Chuang Li1, Caleb Marlin1, Kyle Wright3, Kandice Tessneer1, Lida Radfar4, Judith James1, Robert Scofield1, Indra Adrianto5, Astrid Rasmussen1, Joel Guthridge1, A. Darise Farris1 and Christopher Lessard1, 1Oklahoma Medical Research Foundation, Oklahoma City, OK, 2University Medical Center Groningen, Groningen, Netherlands, 3University of Oklahoma Health Sciences Center, Oklahoma City, OK, 4University of Oklahoma College of Dentistry, Oklahoma City, OK, 5Henry Ford Health, Detroit, MI

    Background/Purpose: 10X Visium spatial transcriptomics evaluates gene expression in a 50μm tile coordinate of a sectioned tissue, yielding heterogeneous cell sampling. Spatial PCA algorithm was…
  • Abstract Number: 1296 • ACR Convergence 2023

    Decline in Incidence of Extraarticular Manifestations of Rheumatoid Arthritis: A Population-Based Cohort Study

    Bradly Kimbrough1, Cynthia Crowson1, John Davis1, Eric Matteson2 and Elena Myasoedova1, 1Mayo Clinic, Rochester, MN, 2Mayo Clinic College of Medicine and Science, Rochester, MN, USA, Rochester, MN

    Background/Purpose: Extraarticular manifestations of rheumatoid arthritis (ExRA) are associated with increased disease burden and mortality. They are also common, affecting about half of patients with…
  • Abstract Number: 1380 • ACR Convergence 2023

    Synergistic Dose Effects of Extra X Chromosome in Development of Sjogren’s Syndrome in Klinefelter and Triple X Syndromes

    Anna-Kay Palmer1 and Irene Tan2, 1Albert Einstein Medical Center, Philadelphia, PA, 2Einstein Medical Center Philadelphia, Bala Cynwyd, PA

    Background/Purpose: Immune-related genes located on the X chromosome are known to be important in the regulation of sex hormones and immune tolerance. It has been…
  • Abstract Number: 2181 • ACR Convergence 2023

    Secretagogue Effect of PDE4 Inhibitor Apremilast on Human Salivary Gland Organoids Obtained from Primary Sjögren’s Syndrome Patients

    Valeria Manfrè1, Salvatore Parisi2, Isabella Caligiuri2, Ombretta Repetto3, Alen Zabotti1, Enrico Pegolo4, Cinzia Fabro1, Salvatore De Vita1, Vincenzo Canzonieri2, Carla Di Loreto4, Flavio Rizzolio2 and Luca Quartuccio1, 1Division of Rheumatology, Department of Medicine, University of Udine, Udine, Italy, 2Pathology Unit, Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, Aviano, Italy, 3Facility of Bio-Proteomics, Immunopathology and Cancer Biomarkers, Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, Aviano, Italy, 4Institute of Pathology, Azienda Sanitaria Universitaria Friuli Centrale c/o Università degli studi di Udine, Udine, Italy

    Background/Purpose: In primary Sjögren's syndrome (pSS), salivary epithelial cells show an active role in the initiation and reiteration of the immunomediated damage. Epithelial saliva production…
  • Abstract Number: PP12 • ACR Convergence 2023

    Sjögren’s-Fatigue: Non-Therapeutic Lifestyle Adjustments to Help Manage My Most Problematic Symptom

    Susan Barajas, Sjögren's Foundation, Los Angeles, CA

    Background/Purpose: I was diagnosed with Sjögren's disease in 2015. I sought help from a rheumatologist after experiencing hand pain. I also had dry eyes and…
  • Abstract Number: 021 • 2023 Pediatric Rheumatology Symposium

    Distinguishing Childhood Sjogren’s Disease in Patients Presenting with Recurrent Sialadenitis in a Multidisciplinary Clinic

    Anna Holley1 and Sara Stern2, 1University of Utah School of Medicine, Salt Lake City, UT, 2University of Utah Department of Pediatrics, Salt Lake City, UT

    Background/Purpose: Sialadenitis is a common distinguishing manifestation of Childhood Sjogrens Disease (cSD). We have previously reported a surprisingly high rate of Childhood Sjogrens Disease (cSD)…
  • Abstract Number: 114 • 2023 Pediatric Rheumatology Symposium

    Clinical Significance of SSA and SSB Antibodies in Pediatric SLE Patients: A Single Center Cohort

    Yiressy Pina1, Dawn Janysek1, Danielle Guffey2, Maria Pereira Palacios3 and Marietta De Guzman1, 1Baylor College of Medicine, Texas Children's Hospital, Houston, TX, 2Baylor College of Medicine, Houston, TX, 3Baylor College of Medicine, Texas Children's Hospital, Houston, TX

    Background/Purpose: Anti-nuclear antibodies (ANA) are important in the diagnosis of Systemic Lupus Erythematosus (SLE). Of the disease specific ANAs, anti-dsDNA and anti- Smith antibodies carry…
  • Abstract Number: L13 • ACR Convergence 2022

    Fetal Cardiac Targets Identify the Autoantibodies Associated with Congenital Heart Block

    Stephanie Benjamin1, Lisa Vi2, Diptendu Chatterjee1, Edgar Jaeggi1, Marie Wahren-Herlenius3, Amelia Ruffatti4, Linda Hiraki5, Michelle Lohbihler2, Lusia Sepiashvili1, Carl Laskin6, Meena Fatah1, Daniela Dominguez5, Lawrence Ng5, Anthony Gramolini2, Vincent Christoffels7, Stephanie Protze2 and Robert Hamilton8, 1Hospital for Sick Children, Toronto, ON, Canada, 2University of Toronto, Toronto, ON, Canada, 3Karolinska Institutet, Stockholm, Stockholms Lan, Sweden, 4Universitå di Padova, Padova, Italy, 5The Hospital for Sick Children, Toronto, ON, Canada, 6Mt. Sinai Hospital/University of Toronto, Toronto, ON, Canada, 7Amsterdam UMC, Amsterdam, Zuid-Holland, Netherlands, 8Hospital for Sick Children, Markham, ON, Canada

    Background/Purpose: Autoimmune congenital heart block (CHB+) affects the fetus of mothers with anti-Ro antibodies. Anti-Ro (Ro+) antibodies (Abs) are usually present in maternal sera when…
  • Abstract Number: 0013 • ACR Convergence 2022

    Binding of CXCL13 with Heparan Sulfate of Syndecan-1 Plays an Important Role in Pathogenesis of Sjögren’s Syndrome

    Eon Jeong Nam1, Na Ri Kim1 and Gun Woo Kim2, 1Kyungpook National University Chilgok Hospital, Daegu, Republic of Korea, 2Daegu Fatima Hospital, Daegu, Republic of Korea

    Background/Purpose: Sjögren's syndrome (SS) is a chronic autoimmune disorder with lymphocytic infiltration in exocrine and non-exocrine epithelia, in which epithelial cells play a critical role…
  • Abstract Number: 1628 • ACR Convergence 2022

    The Sjogren Tool for Assessing Response (STAR): Assessment of Response Rates Overall, According to Baseline Activity and by Domain: Reanalysis of 9 Clinical Trials in Primary Sjogren Syndrome

    Raphaèle Seror1, Gabriel Baron2, Divi CORNEC3, Elodie Perrodeau2, Marine Camus4, Professor Simon Bowman5, Michele Bombardieri6, Hendrika Bootsma7, Suzanne Arends7, jacques-eric gottenberg8, Benjamin A. Fisher9, Wolfgang Hueber10, Joel Van Roon11, Valerie Devauchelle12, Liseth de Wolff13, Peter Gergely14, Xavier Mariette15 and Raphaël Porcher16, 1University Hospital Paris-Saclay, Le Kremlin Bicêtre, France, 2AP-HP Hôtel Dieu Hospital, Université Paris Descartes, Paris, France, 3CHRU Brest, Brest, France, 4Department of Rheumatology, Université Paris-Saclay, APHP Hôpital Bicêtre, Le Kremlin Bicêtre, France, 5University Hospitals Birmingham, Birmingham, United Kingdom, 6Experimental Medicine and Rheumatology, William Harvey Research Institute, Queen Mary University, London, United Kingdom, 7University Medical Center Groningen, Groningen, Netherlands, 8Strasbourg University Hospital, Strasbourg, France, 9University of Birmingham, Birmingham, United Kingdom, 10Novartis Pharmaceuticals, Basel, Switzerland, 11Rheumatology & Clinical Immunology, University of Utrecht, Utrecht, Netherlands, 12Université de Bretagne Occidentale, Brest, France, 13UMCG, Zwolle, Netherlands, 14Novartis Pharma, Basel, Switzerland, 15Paris-Saclay University, Rueil Malmaison, Ile-de-France, France, 16Université Paris Cité, Hôtel-Dieu, Paris, France

    Background/Purpose: The ESSDAI and ESSPRI, used alone, are not able to capture all features of primary Sjögren's syndrome (pSS). The NECESSITY consortium developed the Sjögren's…
  • Abstract Number: 2028 • ACR Convergence 2022

    The Value of FDG-PET/CT in the Detection of Lymphomas Associated with Primary Sjögren’s Syndrome

    Martha S. van Ginkel1, Andor WJM Glaudemans1, Bert van der Vegt1, Arjan Vissink1, Frans Kroese2 and Hendrika Bootsma2, 1University Medical Center Groningen, University of Groningen, Groningen, Netherlands, 2University Medical Center Groningen, Groningen, Netherlands

    Background/Purpose: Primary Sjögren's syndrome (pSS) patients have an increased risk of developing a lymphoma. PSS-associated lymphomas are mostly of the mucosa associated lymphoid tissue (MALT)…
  • Abstract Number: 2044 • ACR Convergence 2022

    Abnormalities of Extracellular Matrix Modeling Gene Expression in Salivary Gland Epithelial Cells of Patients with Sjögren’s Syndrome

    Elodie Riviere1, Juliette Pascaud1, Franck Letourneur2, Gaetane Nocturne3 and Xavier Mariette4, 1Université Paris-Saclay, INSERM U1184, Le Kremlin Bicêtre, France, 2Genomic, Hôpital Cochin, Université Paris Descartes, Sorbonne Paris Cité, Paris, France, 3APHP, Le Kremlin Bicêtre, France, 4Paris-Saclay University, Rueil Malmaison, Ile-de-France, France

    Background/Purpose: Salivary gland epithelial cells (SGECs) are not only the target of autoimmunity in primary Sjögren's syndrome (pSS). SGECs may interact with lymphocytes and therefore…
  • Abstract Number: 0559 • ACR Convergence 2022

    JAK Inhibitor Withdrawal Causes a Transient Proinflammatory Signaling Cascade in Minor Salivary Gland Mesenchymal Stromal Cells

    Ilya Gurevic, jacques Galipeau and Sara McCoy, University of Wisconsin, Madison, WI

    Background/Purpose: Sjögren's Disease (SjD) has high glandular IFNg levels, associated with disease activity and lymphoma risk. We previously showed IFNg-stimulated minor salivary gland (SG)-mesenchymal stromal…
  • « Previous Page
  • 1
  • …
  • 15
  • 16
  • 17
  • 18
  • 19
  • …
  • 24
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology